{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-068545","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.513110+00:00","generated_at":"2026-06-18T04:40:40.454036+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acrivon reports $169.6M cash, runway into Q4 2024; ACR-368 OncoSignature enriches ORR to 47-58% in ovarian cancer","bullets":["Cash and marketable securities $169.6M as of Dec 31, 2022 (preliminary, unaudited); projected runway into at least Q4 2024.","ACR-368 OncoSignature test enriched ORR to 47% (NCI) and 58% (Lilly) in blinded studies of platinum-resistant ovarian cancer biopsies.","Registrational-intent Phase 2 single-arm trials of ACR-368 monotherapy in OncoSignature-positive patients planned for ovarian, endometrial, bladder, and HPV SCC cancers.","Internal WEE1 and PKMYT1 inhibitors advancing to IND-enabling studies in 2023.","Past Phase 2 all-comer ORR for ACR-368 in platinum-resistant ovarian cancer was 12.1%; mDoR 5.6 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-068545","json":"https://secwatch.observer/filing/0001193125-23-068545.json","markdown":"https://secwatch.observer/filing/0001193125-23-068545.md","text":"https://secwatch.observer/filing/0001193125-23-068545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523068545/0001193125-23-068545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523068545/d385129d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:40:40.454036+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}